Reuters logo
BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza
October 25, 2017 / 8:15 PM / a month ago

BRIEF-Neurocrine initiates Phase IIb clinical study of Ingrezza

Oct 25 (Reuters) - Neurocrine Biosciences Inc

* Neurocrine initiates phase IIb clinical study of once-daily Ingrezza in children and adolescents with Tourette syndrome

* Neurocrine Biosciences Inc - ‍top-line data from study is expected in late 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below